These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30459247)

  • 1. Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.
    Menon V; Lincoff AM; Nicholls SJ; Jasper S; Wolski K; McGuire DK; Mehta CR; Rosenstock J; Lopez C; Marcinak J; Cao C; Nissen SE;
    Diabetes Care; 2018 Dec; 41(12):2603-2609. PubMed ID: 30459247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
    Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
    Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.
    Marcinak J; Cao C; Lee D; Ye Z
    Diabetes Obes Metab; 2017 Dec; 19(12):1714-1721. PubMed ID: 28493502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
    Bain SC; Mosenzon O; Arechavaleta R; Bogdański P; Comlekci A; Consoli A; Deerochanawong C; Dungan K; Faingold MC; Farkouh ME; Franco DR; Gram J; Guja C; Joshi P; Malek R; Merino-Torres JF; Nauck MA; Pedersen SD; Sheu WH; Silver RJ; Tack CJ; Tandon N; Jeppesen OK; Strange M; Thomsen M; Husain M
    Diabetes Obes Metab; 2019 Mar; 21(3):499-508. PubMed ID: 30284349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
    Lee RD; Nudurupati S; Marcinak J; Viswanathan P
    Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
    Gantz I; Chen M; Suryawanshi S; Ntabadde C; Shah S; O'Neill EA; Engel SS; Kaufman KD; Lai E
    Cardiovasc Diabetol; 2017 Sep; 16(1):112. PubMed ID: 28893244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Alfredsson J; Green JB; Stevens SR; Reed SD; Armstrong PW; Angelyn Bethel M; Engel SS; McGuire DK; Van de Werf F; Hramiak I; White HD; Peterson ED; Holman RR;
    Diabetes Obes Metab; 2018 Oct; 20(10):2379-2388. PubMed ID: 29923323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
    Marx N; McGuire DK; Perkovic V; Woerle HJ; Broedl UC; von Eynatten M; George JT; Rosenstock J
    Diabetes Care; 2017 Sep; 40(9):1144-1151. PubMed ID: 28830955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
    Tolman KG; Freston JW; Kupfer S; Perez A
    Drug Saf; 2009; 32(9):787-800. PubMed ID: 19670918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
    Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
    Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
    Zinman B; Marso SP; Christiansen E; Calanna S; Rasmussen S; Buse JB;
    Diabetes Care; 2018 Aug; 41(8):1783-1791. PubMed ID: 29903847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
    Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
    Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
    White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
    Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.